Last deal

$132.2M

Amount

Post-IPO Equity

Stage

14.06.2021

Date

10

all rounds

$389M

Total amount

General

About Company
Protagonist Therapeutics develops orally-stable peptides to treat diseases that are currently addressed by injectable antibodies.

Industry

Sector :

Subsector :

Keywords :

Also Known As

Cytokine Mimetics

founded date

01.01.2001

Number of employees

Company Type

For Profit

Last funding type

Post-IPO Equity

IPO status

Private

Description

Protagonist Therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities (NCEs) that can potentially transform existing treatment paradigms in disease areas with significant unmet medical needs. Their platform enables them to discover peptides in a de novo fashion with the desired degree of potency, specificity, and selectivity, and also engineer oral stability with specific peptidomimetic and chemical modifications. The Company operates and manages its business as one operating segment and is dedicated to the discovery of novel peptide and small molecule compounds that mimic or inhibit therapeutically-relevant protein-protein interactions.